Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Verified
Added on 2023/06/10
|11
|9452
|124
AI Summary
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score.
Contribute Materials
Your contribution can guide someone’s learning journey. Share your
documents today.